THERAVANCE BIOPHARMA INC's ticker is TBPH and the CUSIP is G8807B106. A total of 106 filers reported holding THERAVANCE BIOPHARMA INC in Q1 2020. The put-call ratio across all filers is 2.19 and the average weighting 0.8%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q1 2020 | $1,005,000 | -45.0% | 43,480 | -38.4% | 0.10% | -3.8% |
| Q4 2019 | $1,827,000 | +14.4% | 70,585 | -13.9% | 0.10% | +38.2% |
| Q3 2019 | $1,597,000 | +84.2% | 81,960 | +54.5% | 0.08% | +94.9% |
| Q2 2019 | $867,000 | -28.2% | 53,065 | -0.4% | 0.04% | -17.0% |
| Q1 2019 | $1,208,000 | -12.3% | 53,265 | -1.1% | 0.05% | -16.1% |
| Q4 2018 | $1,378,000 | – | 53,860 | – | 0.06% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Link Fund Solutions Ltd | 5,251,349 | $135,459,000 | 69.86% |
| Chescapmanager LLC | 949,006 | $24,570,000 | 3.61% |
| Baupost Group | 9,309,168 | $241,014,000 | 2.66% |
| Rock Springs Capital Management LP | 655,200 | $16,963,000 | 0.54% |
| Rubric Capital Management LP | 173,400 | $4,489,000 | 0.51% |
| Newtyn Management, LLC | 173,300 | $4,487,000 | 0.41% |
| NJ State Employees Deferred Compensation Plan | 38,142 | $988,000 | 0.17% |
| King Wealth Management Group | 22,500 | $583,000 | 0.15% |
| Virtus ETF Advisers LLC | 29,216 | $756,000 | 0.12% |
| JACOBS LEVY EQUITY MANAGEMENT, INC | 452,615 | $11,718,000 | 0.12% |